NCT01446718View on ClinicalTrials.gov

A Cohort Study to Assess Sustained Immunogenicity to qHPV Vaccine Among HIV-infected Girls and Boys Age 9-14 Years

CompletedOBSERVATIONAL
Enrollment

179

Participants

Timeline

Start Date

December 15, 2014

Primary Completion Date

June 30, 2018

Study Completion Date

June 30, 2018

Conditions
Human PapillomavirusHIV-1 Infection
Interventions
BIOLOGICAL

Gardasil vaccine

0.5ml of intramuscular vaccine in three doses

Sponsors
All Listed Sponsors
collaborator

University of Washington

OTHER

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Kenya Medical Research Institute

OTHER

NCT01446718 - A Cohort Study to Assess Sustained Immunogenicity to qHPV Vaccine Among HIV-infected Girls and Boys Age 9-14 Years | Biotech Hunter | Biotech Hunter